Fountain Life Closes $18M Series B for Longevity Growth

Fountain Life, the longevity company co-founded by Dr. William Kapp, Dr. Peter Diamandis, and Tony Robbins, secured $18 million in Series B funding. EOS Ventures led this round. This investment supports Fountain Life's expansion of its preventative health services.

The company focuses on early detection and health optimization. It utilizes advanced screening methods, including blood tests and body scans, to analyze over 100 biomarkers. Fountain Life aims to identify illnesses and chronic conditions at their earliest, often asymptomatic, stages.

Fountain Life previously raised an $80 million Series A round, bringing its total funding to $108 million. This Fountain Life Series B round saw participation from most existing board members. The board includes Todd Wanek and B.K. Modi as investors, with Dr. Bob Hariri serving as an advisor.

Expanding Longevity Care

The new capital will facilitate the opening of additional centers. Fountain Life currently operates four centers in Naples, Westchester, Orlando, and Dallas. A Houston center opens in December, with Los Angeles and Miami locations planned for Q2 2026.

Fountain Life offers comprehensive annual subscriptions, priced at $21,500. A testing-only package costs $10,500. Members receive quarterly testing and track results via an AI-powered app. This approach emphasizes proactive health management.

Fountain Life operates alongside other specialized providers like Function Health and Human Longevity. The company plans to address affordability by training other medical facilities in its methodologies, aiming to reduce access costs for preventative health services.